{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:13:33Z","timestamp":1788484413328,"version":"build-2803163510"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573325"],"award-info":[{"award-number":["82573325"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218769","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:26:02Z","timestamp":1785281162000},"page":"218769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The FGFRL1\u2013FASN axis regulates neuroendocrine lineage transdifferentiation by modulating fatty acid synthesis in AR pathway-independent prostate cancer"],"prefix":"10.1016","volume":"658","author":[{"given":"Yupeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusen","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailiyaerjiang","family":"Wureyimu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongda","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintai","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0430-2845","authenticated-orcid":false,"given":"Weide","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.canlet.2026.218769_bib1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.canlet.2026.218769_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/15384047.2018.1423926","article-title":"Androgen receptor-independent prostate cancer: an emerging clinical entity[J\/OL]","volume":"19","author":"Sahin","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"3","key":"10.1016\/j.canlet.2026.218769_bib3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41391-021-00332-5","article-title":"Clinical considerations for the management of androgen indifferent prostate cancer[J\/OL]","volume":"24","author":"Berchuck","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"8","key":"10.1016\/j.canlet.2026.218769_bib4","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/ERC-21-0140","article-title":"Therapy considerations in neuroendocrine prostate cancer: what next?[J\/OL]","volume":"28","author":"Beltran","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"issue":"7","key":"10.1016\/j.canlet.2026.218769_bib5","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41388-020-01598-0","article-title":"Loss and revival of androgen receptor signaling in advanced prostate cancer[J\/OL]","volume":"40","author":"Formaggio","year":"2021","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.canlet.2026.218769_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.70176","article-title":"Proteomic profiling of extracellular vesicles distinguishes prostate cancer molecular Subtypes[J\/OL]","volume":"14","author":"Ludwig","year":"2025","journal-title":"J. Extracell. Vesicles"},{"issue":"10","key":"10.1016\/j.canlet.2026.218769_bib7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00432-024-05983-0","article-title":"Unraveling molecular characteristics and tumor microenvironment dynamics of neuroendocrine prostate cancer[J\/OL]","volume":"150","author":"Heimd\u00f6rfer","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218769_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.34133\/research.0791","article-title":"New insights into potential therapeutic targets for neuroendocrine prostate cancer: from bench to clinic","volume":"8","author":"Cai","year":"2025","journal-title":"Research"},{"key":"10.1016\/j.canlet.2026.218769_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108255","article-title":"Current and emerging therapies for neuroendocrine prostate cancer","volume":"238","author":"Alabi","year":"2022","journal-title":"Pharmacol. Therapeut."},{"issue":"10","key":"10.1016\/j.canlet.2026.218769_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.761","article-title":"Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets","volume":"5","author":"Jiang","year":"2024","journal-title":"MedComm"},{"issue":"3","key":"10.1016\/j.canlet.2026.218769_bib11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.canlet.2026.218769_bib12","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218769_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217808","article-title":"Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B \u03b2-hydroxybutyrylation","volume":"625","author":"Jiang","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib14","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1038\/s41467-023-43676-3","article-title":"The ELAVL3\/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer","volume":"14","author":"Ji","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218769_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217986","article-title":"Chimeric antigen receptor-engineered (CAR)-T cell therapy for metastatic prostate cancer","volume":"632","author":"Tharian","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"6611","key":"10.1016\/j.canlet.2026.218769_bib17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1126\/science.abn0478","article-title":"Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling","volume":"377","author":"Chan","year":"2022","journal-title":"Science"},{"issue":"0","key":"10.1016\/j.canlet.2026.218769_bib18","article-title":"Hallmarks of cancer\u2014Then and now, and beyond","volume":"0","author":"Hanahan","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218769_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217617","article-title":"Organoid-based single cell sequencing revealed the lineage evolution during docetaxel treatment in gastric cancer","volume":"619","author":"Yang","year":"2025","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.canlet.2026.218769_bib20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","article-title":"An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer","volume":"23","author":"Davies","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218769_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1191311","article-title":"Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution","volume":"14","author":"Imamura","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218769_bib22","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/2159-8290.CD-23-0539","article-title":"ZNF397 deficiency triggers TET2-Driven lineage plasticity and AR-Targeted therapy resistance in prostate cancer","volume":"14","author":"Xu","year":"2024","journal-title":"Cancer Discov."},{"issue":"6320","key":"10.1016\/j.canlet.2026.218769_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2548975","article-title":"Mechanisms of neuroendocrine differentiation in castration-resistant prostate cancer and advances in the treatment of neuroendocrine prostate cancer","volume":"57","author":"Shao","year":"2025","journal-title":"Ann. Med."},{"key":"10.1016\/j.canlet.2026.218769_bib25","first-page":"2024","article-title":"The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1","author":"Romero","year":"2024","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.canlet.2026.218769_bib26","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1172\/JCI127961","article-title":"N-myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer","volume":"129","author":"Berger","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib27","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","article-title":"Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","volume":"15","author":"Venkadakrishnan","year":"2024","journal-title":"Nat. Commun."},{"issue":"6320","key":"10.1016\/j.canlet.2026.218769_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer[J\/OL]","volume":"355","author":"Mu","year":"2017","journal-title":"Science (New York, N.Y.)"},{"issue":"4","key":"10.1016\/j.canlet.2026.218769_bib29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41374-019-0343-5","article-title":"SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer[J\/OL]","volume":"100","author":"Li","year":"2020","journal-title":"Laboratory Invest.; J. Tech. Methods Pathol."},{"issue":"13","key":"10.1016\/j.canlet.2026.218769_bib30","doi-asserted-by":"crossref","first-page":"7740","DOI":"10.1093\/nar\/gkae547","article-title":"ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer","volume":"52","author":"Qian","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"21","key":"10.1016\/j.canlet.2026.218769_bib31","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-24-2913","article-title":"ASCL1 drives the development of neuroendocrine prostate cancer","volume":"84","author":"Mcquillen","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218769_bib32","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1038\/s41467-024-49234-9","article-title":"FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218769_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217355","article-title":"PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer","volume":"609","author":"Muniyan","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13046-024-03064-1","article-title":"PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET\/STAT5A-mediated chromatin accessibility","volume":"43","author":"Jing","year":"2024","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"6","key":"10.1016\/j.canlet.2026.218769_bib35","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41418-024-01295-5","article-title":"Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cell Death Differ."},{"issue":"11","key":"10.1016\/j.canlet.2026.218769_bib36","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ccell.2022.10.011","article-title":"FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer","volume":"40","author":"Han","year":"2022","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.canlet.2026.218769_bib37","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1158\/0008-5472.CAN-21-1392","article-title":"Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon?","volume":"81","author":"Sena","year":"2021","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2026.218769_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70126","article-title":"Depletion of acetyl\u2010CoA carboxylase 1 facilitates epithelial\u2010mesenchymal transition in prostate cancer cells by activating the MAPK\/ERK pathway","volume":"6","author":"Lai","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218769_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217441","article-title":"Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer","volume":"611","author":"Hindes","year":"2025","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2026.218769_bib40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","article-title":"Cellular fatty acid metabolism and cancer","volume":"18","author":"Currie","year":"2013","journal-title":"Cell Metab."},{"issue":"12","key":"10.1016\/j.canlet.2026.218769_bib41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41568-021-00388-4","article-title":"Tumour fatty acid metabolism in the context of therapy resistance and obesity","volume":"21","author":"Hoy","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218769_bib42","article-title":"Targeting fatty acid uptake and metabolism in cancer cells: a promising strategy for cancer treatment","volume":"167","author":"Mallick","year":"2023","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/1541-7786.MCR-20-0379","article-title":"Long-chain acyl-CoA synthetase 4-mediated fatty acid metabolism sustains androgen receptor pathway-independent prostate cancer","volume":"19","author":"Ma","year":"2021","journal-title":"Mol. Cancer Res.: MCR"},{"issue":"6","key":"10.1016\/j.canlet.2026.218769_bib44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2024.04.007","article-title":"Emerging targets in lipid metabolism for cancer therapy","volume":"45","author":"Terry","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib45","first-page":"143","article-title":"Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer","volume":"4","author":"Chetta","year":"2021","journal-title":"Cancer Drug Resist. (Alhambra, Calif.)"},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41389-023-00460-8","article-title":"Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies","volume":"12","author":"Vanauberg","year":"2023","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2026.218769_bib48","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrc.2016.89","article-title":"The multifaceted roles of fatty acid synthesis in cancer","volume":"16","author":"R\u00f6hrig","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218769_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217992","article-title":"Synergistic targeting of FASN and HMGCS1 by cerulenin enhances tumor cell ferroptosis sensitivity through rewiring lipid metabolism and blocking GPX4 biosynthesis","volume":"633","author":"Xia","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102720","article-title":"Acetyl-CoA carboxylase 1 depletion suppresses de novo fatty acid synthesis and mitochondrial \u03b2-oxidation in castration-resistant prostate cancer cells","volume":"299","author":"Liu","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218769_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217694","article-title":"Metformin inhibits the progression of castration-resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP\/PKG pathway activation","volume":"622","author":"Cai","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218769_bib52","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12964-025-02363-0","article-title":"ACACA depletion activates the cPLA2\u2013arachidonic acid\u2013NF-\u03baB axis to drive inflammatory reprogramming in androgen receptor-independent prostate cancer","volume":"23","author":"Liu","year":"2025","journal-title":"Cell Commun. Signal. : CCS"},{"issue":"10","key":"10.1016\/j.canlet.2026.218769_bib53","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.21037\/tau-2025-490","article-title":"Targeting FGFR1 enhances olaparib sensitivity via MAPK-mediated BRCA2 downregulation in mCRPC","volume":"14","author":"Chen","year":"2025","journal-title":"Transl. Androl. Urol."},{"issue":"43","key":"10.1016\/j.canlet.2026.218769_bib54","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J\/OL]","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"9","key":"10.1016\/j.canlet.2026.218769_bib55","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","article-title":"Ectopic JAK\u2013STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance[J\/OL]","volume":"3","author":"Deng","year":"2022","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib56","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s42003-020-01476-1","article-title":"Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer","volume":"3","author":"Dong","year":"2020","journal-title":"Commun. Biol."},{"issue":"38","key":"10.1016\/j.canlet.2026.218769_bib57","doi-asserted-by":"crossref","first-page":"14839","DOI":"10.1074\/jbc.RA118.002907","article-title":"Ectopic fibroblast growth factor receptor 1 promotes inflammation by promoting nuclear factor-\u03baB signaling in prostate cancer cells","volume":"293","author":"Wang","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib58","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1186\/s12885-017-3729-z","article-title":"Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma","volume":"17","author":"Tsai","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218769_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"issue":"6","key":"10.1016\/j.canlet.2026.218769_bib60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"issue":"13","key":"10.1016\/j.canlet.2026.218769_bib61","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.canlet.2026.218769_bib62","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2026.218769_bib63","article-title":"Dimensionality reduction for visualizing single-cell data using UMAP","author":"Becht","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218769_bib64","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","article-title":"UCell: robust and scalable single-cell gene signature scoring","volume":"19","author":"Andreatta","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib65","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1038\/s41467-021-26840-5","article-title":"Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression","volume":"12","author":"Bolis","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.canlet.2026.218769_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115828","article-title":"An integrated proteomic portrait of prostate cancer progression","volume":"44","author":"Zhang","year":"2025","journal-title":"Cell Rep."},{"issue":"13","key":"10.1016\/j.canlet.2026.218769_bib67","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1038\/emboj.2011.158","article-title":"The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis","volume":"30","author":"Massie","year":"2011","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.canlet.2026.218769_bib68","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41416-024-02762-z","article-title":"Metabolic adaptations in prostate cancer","volume":"131","author":"Pujana-Vaquerizo","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2026.218769_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.01.018","article-title":"Increased serine and one-carbon pathway metabolism by PKC\u03bb\/\u03b9 deficiency promotes neuroendocrine prostate cancer","volume":"35","author":"Reina-Campos","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218769_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101466","article-title":"Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier","volume":"59","author":"Xu","year":"2022","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.canlet.2026.218769_bib71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41392-024-01981-3","article-title":"Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib72","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.molcel.2019.10.014","article-title":"Lineage-restricted regulation of SCD and fatty acid saturation by MITF controls melanoma phenotypic plasticity","volume":"77","author":"Vivas-Garc\u00eda","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218769_bib73","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s42255-023-00861-4","article-title":"Metabolic plasticity in therapy-resistant melanoma","volume":"5","author":"Redondo-Mu\u00f1oz","year":"2023","journal-title":"Nat. Metab."},{"issue":"16","key":"10.1016\/j.canlet.2026.218769_bib74","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1158\/0008-5472.CAN-17-3226","article-title":"Aberrant FGFR tyrosine kinase signaling enhances the warburg effect by reprogramming LDH isoform expression and activity in prostate cancer","volume":"78","author":"Liu","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218769_bib76","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218769_bib77","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/s41419-021-03966-4","article-title":"Targeting the Lnc-OPHN1-5\/androgen receptor\/hnRNPA1 complex increases enzalutamide sensitivity to better suppress prostate cancer progression","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218769_bib78","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.canlet.2018.11.008","article-title":"Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen enzalutamide sensitivity to better suppress castration-resistant prostate cancer growth","volume":"442","author":"Zhang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218769_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217668","article-title":"Selective degradation of FGFR1\/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1\/2 alterations","volume":"619","author":"Uemoto","year":"2025","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.canlet.2026.218769_bib80","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.31557\/APJCP.2023.24.4.1331","article-title":"Aberrant expression of FGFRL1 in esophageal cancer and its regulation by miR-107[J\/OL]","volume":"24","author":"Sharma","year":"2023","journal-title":"Asian Pac. J. Cancer Prev. APJCP : Asian Pac. J. Cancer Prev. APJCP"},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ydbio.2020.01.003","article-title":"Functional domains of the FgfrL1 receptor","volume":"461","author":"Gerber","year":"2020","journal-title":"Dev. Biol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218769_bib82","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/cimb47040286","article-title":"FGFRL1: structure, molecular function, and involvement in human disease","volume":"47","author":"Guan","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218769_bib83","article-title":"Distinct effects of SDC3 and FGFRL1 on selective neurodegeneration in AD and PD","volume":"37","author":"Wang","year":"2023","journal-title":"FASEB (Fed. Am. Soc. Exp. Biol.) J.: Off. Publ. Feder. Am. Soc. Experiment. Biol."},{"key":"10.1016\/j.canlet.2026.218769_bib84","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.mce.2017.09.015","article-title":"Role of fibroblast growth factor receptors (FGFR) and FGFR like-1 (FGFRL1) in mesenchymal stromal cell differentiation to osteoblasts and adipocytes","volume":"461","author":"K\u00e4hk\u00f6nen","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib85","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ydbio.2009.08.019","article-title":"The murine Fgfrl1 receptor is essential for the development of the metanephric kidney","volume":"335","author":"Gerber","year":"2009","journal-title":"Dev. Biol."},{"issue":"23","key":"10.1016\/j.canlet.2026.218769_bib86","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1111\/j.1742-4658.2007.06143.x","article-title":"Mice with a targeted disruption of the Fgfrl1 gene die at birth due to alterations in the diaphragm","volume":"274","author":"Baertschi","year":"2007","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.canlet.2026.218769_bib87","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/cancers14020278","article-title":"Increased expression and altered cellular localization of fibroblast growth factor receptor-like 1 (FGFRL1) are associated with prostate cancer progression","volume":"14","author":"Yu","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.canlet.2026.218769_bib88","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/jcmm.14763","article-title":"FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K\/Akt pathway via ENO1","volume":"24","author":"Chen","year":"2020","journal-title":"J. Cell Mol. Med."},{"issue":"43","key":"10.1016\/j.canlet.2026.218769_bib89","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1038\/sj.onc.1208802","article-title":"PKB\/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP[J\/OL]","volume":"24","author":"Porstmann","year":"2005","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.canlet.2026.218769_bib90","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-07-2489","article-title":"Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and SREBP-1","volume":"68","author":"Furuta","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib91","first-page":"165","article-title":"ONECUT2 as a key mediator of androgen receptor-independent cell growth and neuroendocrine differentiation in castration-resistant prostate cancer","volume":"5","author":"Choi","year":"2022","journal-title":"Cancer Drug Resist."},{"issue":"2","key":"10.1016\/j.canlet.2026.218769_bib92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41585-018-0136-4","article-title":"ONECUT2 many towards AR-independence","volume":"16","author":"Bradley","year":"2019","journal-title":"Nat. Rev. Urol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218769_bib93","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","article-title":"ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis","volume":"24","author":"Rotinen","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218769_bib94","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","article-title":"ONECUT2 is a driver of neuroendocrine prostate cancer","volume":"10","author":"Guo","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:44:08Z","timestamp":1788482648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526005331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":94,"alternative-id":["S0304383526005331"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218769","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The FGFRL1\u2013FASN axis regulates neuroendocrine lineage transdifferentiation by modulating fatty acid synthesis in AR pathway-independent prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218769"}}